Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002448 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
NCT00002448 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 40 participants.
The verdict
NCT00002448, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to examine how the immune systems of HIV-infected patients react to 2 anti-HIV drug combinations.
Interventions
- DRUG Ritonavir
- DRUG Efavirenz
- DRUG Saquinavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1999-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002448
The ClinicalTrials.gov registry entry for NCT00002448 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ritonavir is the first listed.
NCT00002448 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002448 about?
NCT00002448 is a clinical study titled "A Study to Compare the Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients". The purpose of this study is to examine how the immune systems of HIV-infected patients react to 2 anti-HIV drug combinations.
What is the current status of trial NCT00002448?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 1999-10.
What interventions are being tested in trial NCT00002448?
The interventions under investigation include: Ritonavir (DRUG), Efavirenz (DRUG), Saquinavir (DRUG).
Who is sponsoring clinical trial NCT00002448?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.